glp-1 pills Understanding pills: A new weight loss alternative to injections Clinically backed oral GLP GLP-1 pills: Your guide to

GLP-1 receptor agonists obesity drugs market captured the largest revenue share of 81% in 2024 within North America, driven by high obesity prevalence, early drug approvals, and robust healthcare infrastructure

Zaccardi F, Htike ZZ, Webb DR, Khunti K, Davies MJ

The ability of GLP-1 RAs to passivate or stabilise plaque requires further evaluation in human studies but may be a novel and important mechanism by which this class confers a reduced risk of future and recurrent ischaemic events, including both MI and ischaemic stroke

In these studies, GLP-1 receptor agonist treatment consistently reduced urinary albumin-to-creatinine ratios (UACRs) by 20%40% and new-onset macroalbuminuria in people with T2D (12, 13)

The glucagon receptor raises theoretical concerns about heart rate increases (glucagon is known to increase heart rate), but clinical trial data has not shown significant safety issues in this regard so far

Testing for genetic variants like GLP1R rs6923761 and GIPR rs1800437 helps predict which patients will derive maximal benefit from GLP-1 monotherapy, dual GLP-1/GIP therapy, or might require complementary metabolic support